FamiCord AG (V3V) Fair Value & Analysis
Healthcare · DE · Market cap €69.2M
Fair value as of: Jun 24, 2026
From 5 valuation models · updated 6 days ago
Share price −6.5% over the past month.
Price vs Fair Value (12 months)
12‑month range €3.83 – €7.69 · fair‑value band €1.38 – €2.30 · the €3.83 price screens above the €1.84 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
FamiCord AG (V3V) currently trades at €3.83, while our model-based Fair Value estimate is €1.84 — implying the stock looks roughly 52.0% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, FamiCord AG generated revenue of €88.2M at a net margin of -7.2%. Revenue grew 2.5% year over year. It earns a return on equity of -54.8%. Net debt stands at €11.6M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
FamiCord AG engages in the collection, processing, storage, and distribution of cells, tissues, blood, and blood components for medical applications in Germany, Poland, Switzerland, Portugal, and internationally. The company operates through Subgroup Vita 34 And Subgroup PBKM segments. It produces and develops advanced therapies, genetic tests, and analyses for third parties. The company also engages in the development and manufacture of cell and tissue-based products and pharmaceuticals, including the production of viral vectors or comparable products. In addition, it engages in research and development, storage, and cryopreservation of sperm and oocytes for use in reproductive medicine; and the manufacturing and distribution of medical devices. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is headquartered in Leipzig, Germany.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
FamiCord AG reported revenue of €88.2M in FY2025 versus €28.4M in FY2021, a compound +32.7%/yr. Reported net income was −€6.3M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.47 | $8.55 | -25% |
| 5225 5225 | 8.71 MYR | 4.87 MYR | -44% |
| IHHHF IHHHF | $1.71 | $1.17 | -32% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
| Tenet Healthcare Corporation THC | $178.75 | $300.86 | +68% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is FamiCord AG (V3V) undervalued?
What is the fair value of V3V?
What is the quality score of V3V?
What is the revenue of FamiCord AG (V3V)?
What is the net profit margin of V3V?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.